William J. Phd Link Sells 12,000 Shares of Edwards Lifesciences Corp (EW) Stock

Edwards Lifesciences Corp (NYSE:EW) Director William J. Phd Link sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $122.24, for a total value of $1,466,880.00. Following the transaction, the director now directly owns 24,596 shares in the company, valued at $3,006,615.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Edwards Lifesciences Corp (EW) traded up $0.46 on Tuesday, hitting $127.35. The stock had a trading volume of 1,016,167 shares, compared to its average volume of 1,381,409. The firm has a market cap of $26,750.00, a price-to-earnings ratio of 44.22, a P/E/G ratio of 1.86 and a beta of 0.63. Edwards Lifesciences Corp has a 12 month low of $89.20 and a 12 month high of $138.48. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. Edwards Lifesciences’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.75 EPS. equities analysts anticipate that Edwards Lifesciences Corp will post 4.49 EPS for the current year.

Edwards Lifesciences announced that its board has initiated a stock repurchase program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

A number of research analysts have commented on EW shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $135.00 price objective (down from $155.00) on shares of Edwards Lifesciences in a report on Wednesday, October 25th. Evercore ISI started coverage on Edwards Lifesciences in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price objective on the stock. Morgan Stanley upped their price objective on Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. SunTrust Banks set a $124.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a report on Friday, December 8th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $141.15.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cerebellum GP LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $128,000. Resources Investment Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after purchasing an additional 465 shares in the last quarter. Exane Derivatives grew its holdings in shares of Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock worth $137,000 after purchasing an additional 961 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $140,000. Finally, Dupont Capital Management Corp acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $142,000. 81.11% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “William J. Phd Link Sells 12,000 Shares of Edwards Lifesciences Corp (EW) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/william-j-phd-link-sells-12000-shares-of-edwards-lifesciences-corp-ew-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply